Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Total Non-Current Liabilities data on record, last reported at $51.8 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 23.68% year-over-year to $51.8 million; the TTM value through Dec 2025 reached $51.8 million, up 23.68%, while the annual FY2025 figure was $51.8 million, 23.68% up from the prior year.
  • Total Non-Current Liabilities reached $51.8 million in Q4 2025 per CLDX's latest filing, up from $47.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $51.8 million in Q4 2025 and bottomed at $15.4 million in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $27.5 million, with a median of $27.6 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: surged 104.19% in 2022, then crashed 46.61% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $17.8 million in 2021, then grew by 18.93% to $21.2 million in 2022, then soared by 51.21% to $32.1 million in 2023, then surged by 30.6% to $41.9 million in 2024, then increased by 23.68% to $51.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $51.8 million in Q4 2025, $47.5 million in Q3 2025, and $34.5 million in Q2 2025.